In this issue:
Pembrolizumab efficacious frontline treatment for MSI-H/dMMR metastatic CRC
OPRA: TNT plus watch-and-wait strategy feasible for select rectal cancer
Pembrolizumab may be an option for previously treated advanced anal SCC
BRAF mutations prognostic for poor survival in dMMR/MSI-H CRC
Dual targeting of VEGF and EGFR promising for irinotecan-refractory CRC
Antibiotic use linked to risk of colon, but not rectal, cancer
VOLTAGE: Neoadjuvant chemoradiotherapy plus nivolumab for MSS rectal cancer
Genomic profiles prognostic for survival in CRC with liver metastases
Reduced dose chemotherapy + anti-EGFR for older patients with metastatic CRC
Real-world third-line treatment landscape of metastatic CRC in Australia
Please login below to download this issue (PDF)